BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

...CHMP’s label extension recommendations included Novartis’ Cosentyx secukinumab for active non-radiographic axial spondyloarthritis; and Adcetris brentuximab vedotin...
...Generic), Cosentyx (Other) Sarclisa, isatuximab-irfc (SAR650984) Zeposia, ozanimod (RPC1063) pretomanid, nitroimidazopyran (PA-824) Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
BioCentury | Mar 3, 2020
Product Development

March 2 Quick Takes: FDA Priority Review for MorphoSys-Incyte lymphoma therapy; plus Pfizer-Lilly, Merck, AbbVie, Novartis, Cerovene

...relapsed or refractory classical Hodgkin lymphoma. The anti-PD-1 mAb improved progression-free survival compared with Adcetris brentuximab vedotin...
BioCentury | Jul 25, 2019
Financial News

July 24 Financial Quick Takes: $500M for Seattle Genetics; plus X-Vax, TScan, Alexion and more

...when it proposed the offering. The funds will support commercialization and label expansion of Adcetris brentuximab vedotin...
...by FactSet. Hongjiang Li and Elizabeth S. Eaton, Staff Writers Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
BioCentury | Jul 17, 2019
Company News

July 16 Company Quick Takes: Mazumdar-Shaw, Mukherjee to bring CAR Ts to India; plus Cipla, Celgene, Novartis, Seattle Genetics

...with monomethyl auristatin E (MMAE) (see "Astellas, Seattle Genetics ADC Could Provide New Option" ). Adcetris...
...Seattle Genetics added $4.57 to $67.75 following its 2Q19 earnings report, which showed that Adcetris brentuximab vedotin...
BioCentury | Jun 3, 2019
Clinical News

Astellas, Seattle Genetics ADC could provide new option for checkpoint non-responders in bladder cancer

...November to treat FLT3-positive relapsed/refractory acute myelogenous leukemia (AML). Seattle Genetics markets its ADC Adcetris brentuximab vedotin...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

...retaining U.S. commercialization rights. Its 2009 deal with Takeda yielded its only approved therapy, Adcetris brentuximab vedotin...
...elsewhere. In 2018, Seattle Genetics recorded $476 million in net U.S. and Canada sales of Adcetris...
...Vascular endothelial growth factor (VEGF) Erin McCallister, Senior Editor Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
BioCentury | Mar 28, 2019
Clinical News

Seattle Genetics, Astellas ADC heading for bladder cancer submission

...E (MMAE), and uses the same linker and payload as Seattle Genetics' approved ADC Adcetris brentuximab vedotin...
BioCentury | Feb 16, 2019
Product Development

ADCs’ inflection point

...breast cancer Mkt Seattle Genetics Inc. (NASDAQ:SGEN) / Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) Adcetris brentuximab vedotin...
...failed trials or were discontinued in one or more additional settings. The exception is Adcetris brentuximab vedotin...
...Zymeworks Inc. (TSX:ZYME; NYSE:ZYME), Vancouver, Canada Allison Johnson, Staff Writer Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
BioCentury | Feb 15, 2019
Clinical News

Seattle Genetics gets $30M milestone for EU approval of Adcetris in first-line Hodgkin lymphoma

...Co. Ltd. (Tokyo:4502) triggered by the European Commission's decision to expand the label of Adcetris brentuximab vedotin...
...include previously untreated CD30-positive stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine. Adcetris...
...Osaka, Japan Product: Adcetris brentuximab vedotin (SGN-35) Business: Cancer Sandi Wong Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
BioCentury | Feb 8, 2019
Company News

Seattle Genetics down on light 2019 Adcetris sales guidance

...NASDAQ:SGEN) fell $8.73 (12%) to $65.02 Friday after announcing late Thursday 2019 guidance for Adcetris brentuximab vedotin...
...but the company continues to believe Adcetris will become the standard of care. FDA approved Adcetris...
...$643.7 million. Consensus figures provided by FactSet. Elizabeth S. Eaton Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris...
Items per page:
1 - 10 of 300